KRAS and colorectal carcinoma: This lack of response in the CRC relative to other histologies such as non-small lung cancer, is related to several factors including upstream basal receptor tyrosine kinase activation interfering with KRASG12C inhibitors and feedback suppression of the MAPK signaling with KRAS inhibition.